Hunan Jiudian Pharmaceutical Co Ltd Total Assets
Hunan Jiudian Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Hunan Jiudian Pharmaceutical Co Ltd (300705) holds total assets worth CN¥4.18 Billion CNY (≈ $611.39 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 300705 company net worth for the company's overall valuation and market capitalisation.
Total Assets of Hunan Jiudian Pharmaceutical Co Ltd (2013–2025)
Total assets of Hunan Jiudian Pharmaceutical Co Ltd from 2013 to 2025. This chart illustrates how Hunan Jiudian Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See today's stock price for Hunan Jiudian Pharmaceutical Co Ltd for real-time trading data and today's change.
Hunan Jiudian Pharmaceutical Co Ltd - Asset Composition Analysis
Hunan Jiudian Pharmaceutical Co Ltd Total Assets Breakdown (December 2025)
Hunan Jiudian Pharmaceutical Co Ltd total assets breakdown as of December 2025. Hunan Jiudian Pharmaceutical Co Ltd's total assets of CN¥4.18 Billion consist of 38.3% current assets and 61.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 11.3% |
| Accounts Receivable | CN¥306.51 Million | 7.6% |
| Inventory | CN¥350.68 Million | 8.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥595.36 Million | 14.8% |
| Goodwill | CN¥270.31K | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Hunan Jiudian Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Hunan Jiudian Pharmaceutical Co Ltd current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hunan Jiudian Pharmaceutical Co Ltd's current assets represent 38.3% of total assets in 2025, a decrease from 57.3% in 2013.
- Cash Position: Cash and equivalents constituted 11.3% of total assets in 2025, down from 17.1% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 14.0% of total assets, an increase from 9.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 14.8% of total assets.
Hunan Jiudian Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Hunan Jiudian Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF22.86 Billion |
|
H Lundbeck A/S
CO:HLUN-B
|
Denmark | Dkr54.01 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Viyash Scientific Limited
NSE:SEQUENT
|
India | Rs17.26 Billion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥5.11 Billion |
Hunan Jiudian Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.68 | 4.78 | 3.32 |
| Quick Ratio | 1.92 | 3.60 | 2.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥965.38 Million | CN¥1.29 Billion | CN¥664.65 Million |
Hunan Jiudian Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Hunan Jiudian Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.02 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | 19.1% |
| Total Assets | CN¥4.02 Billion |
| Market Capitalization | $769.42 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hunan Jiudian Pharmaceutical Co Ltd's assets below their book value (0.19x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Hunan Jiudian Pharmaceutical Co Ltd's assets grew by 19.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Hunan Jiudian Pharmaceutical Co Ltd (2013–2025)
The table below shows the annual total assets of Hunan Jiudian Pharmaceutical Co Ltd from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥4.02 Billion ≈ $588.08 Million |
+19.14% |
| 2024-12-31 | CN¥3.37 Billion ≈ $493.60 Million |
+17.48% |
| 2023-12-31 | CN¥2.87 Billion ≈ $420.15 Million |
+24.85% |
| 2022-12-31 | CN¥2.30 Billion ≈ $336.51 Million |
+31.77% |
| 2021-12-31 | CN¥1.75 Billion ≈ $255.38 Million |
+54.35% |
| 2020-12-31 | CN¥1.13 Billion ≈ $165.46 Million |
+5.47% |
| 2019-12-31 | CN¥1.07 Billion ≈ $156.88 Million |
+13.66% |
| 2018-12-31 | CN¥943.21 Million ≈ $138.02 Million |
+22.62% |
| 2017-12-31 | CN¥769.20 Million ≈ $112.56 Million |
+93.74% |
| 2016-12-31 | CN¥397.03 Million ≈ $58.10 Million |
+24.73% |
| 2015-12-31 | CN¥318.32 Million ≈ $46.58 Million |
+18.52% |
| 2014-12-31 | CN¥268.57 Million ≈ $39.30 Million |
+6.51% |
| 2013-12-31 | CN¥252.15 Million ≈ $36.90 Million |
-- |
About Hunan Jiudian Pharmaceutical Co Ltd
Hunan Jiudian Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers chemical drug preparations, active pharmaceutical ingredients (APIs), pharmaceutical excipients, traditional Chinese medicine, health foods, and rehabilitation and wellness products. Its products portfolio includes loxoprofen sodium gel patches,… Read more